Assembly Biosciences
Public biotechnology company and provider of oral biologic therapeutics.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (92 %) | - | - | 298 % | (12 %) | (18 %) | 189 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (790 %) | - | (896 %) | (159 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2076 %) | - | (855 %) | (141 %) | (135 %) | (168 %) | 59 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1096 % | - | 683 % | 196 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Assembly Bio is a biopharmaceutical company dedicated to developing innovative antiviral therapies for serious viral diseases. The company focuses on creating finite and curative treatments for chronic hepatitis B virus (HBV) infection, one of the most prevalent and devastating infectious diseases globally. Assembly Bio also engages in research and preclinical programs aimed at discovering novel antivirals for other serious viral diseases, including hepatitis delta virus (HDV) and herpesviruses. The company operates in the healthcare market, primarily serving patients suffering from chronic viral infections. Assembly Bio's business model revolves around the discovery, development, and commercialization of antiviral therapeutics. Revenue is generated through the sale of these therapeutics, as well as potential partnerships and licensing agreements with other pharmaceutical companies. Assembly Bio's commitment to scientific ingenuity and deep knowledge of virology positions it as a leader in the pursuit of groundbreaking antiviral treatments.
Keywords: antiviral therapies, HBV, HDV, herpesviruses, biopharmaceutical, chronic infections, healthcare, innovative treatments, virology, preclinical research.